Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Windsor

$25,000.00

Synthesis of Irinotecan Metabolites

EF 2012-13

Résumé
Dalton Pharma Services, a developer and manufacturer of pharmaceuticals and fine chemicals, is seeking expertise of Eichhorn's group at the University of Windsor on the synthesis of four valuable impurities of Irinotecan, a fully approved and applied drug for treatment of cancer. Several of these impurities have been analytically identified but not synthesized although their availability as reference compounds (analytical standards) would significantly enhance studies on the decomposition/metabolization of Irinotecan in the human body and elsewhere. In fact, only two impurities are presently commercially available but for a very high price from only three suppliers worldwide. Dalton would like to become the first and sole supplier of four central impurities that are also expected to display potent anti-tumor activity, which is why Dalton expects to sell them not only as reference compounds but also for studies on cancer treatments. Main objective of this project is the development of cost-effective synthetic procedures for each of the four impurities and their preparation in small quantities.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
430047-2012
Name nom
Eichhorn, Holger
Department département
Chemistry and Biochemistry
Organization id
37
Institution établissement
University of Windsor
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Synthesis of Irinotecan Metabolites
Keyword
NSERC
Application summary
Dalton Pharma Services, a developer and manufacturer of pharmaceuticals and fine chemicals, is seeking expertise of Eichhorn's group at the University of Windsor on the synthesis of four valuable impurities of Irinotecan, a fully approved and applied drug for treatment of cancer. Several of these impurities have been analytically identified but not synthesized although their availability as reference compounds (analytical standards) would significantly enhance studies on the decomposition/metabolization of Irinotecan in the human body and elsewhere. In fact, only two impurities are presently commercially available but for a very high price from only three suppliers worldwide. Dalton would like to become the first and sole supplier of four central impurities that are also expected to display potent anti-tumor activity, which is why Dalton expects to sell them not only as reference compounds but also for studies on cancer treatments. Main objective of this project is the development of cost-effective synthetic procedures for each of the four impurities and their preparation in small quantities.